Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TX05 vs Herceptin Adjuvant Extension in HER2+ Early Breast Cancer
NCT04109391Phase 3Completed
- Sponsor
- Tanvex BioPharma, Inc.
- Start
- Aug 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of TrastuRel in HER2-positive breast cancer (3 arms), sponsored by Tanvex BioPharma, Inc. Primary endpoints: Immunogenicity Assessments (ADA and Nab) at Week 45, Disease-Free Survival at Week 45 and 1 more. Started Aug 2019; status: completed.
02
Drugs
TrastuRel
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04109391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109391.